В Финляндии предупредили об опасном шаге ЕС против России09:28
随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
。业内人士推荐91视频作为进阶阅读
What have the government and the BMA said about the dispute?，这一点在雷电模拟器官方版本下载中也有详细论述
Web streams are complex for users and implementers alike. The problems with the spec aren't bugs. They emerge from using the API exactly as designed. They aren't issues that can be fixed solely through incremental improvements. They're consequences of fundamental design choices. To improve things we need different foundations.